After $NOVO B (+3,47 %)
caused a disappointment in Alzheimer's research at the beginning of the week, the company is now back in the headlines - but this time in a positive light. On Tuesday, the Danes reported convincing results from the phase 2 trial with the active ingredient Amycretin in type 2 diabetes patients. All losses from the beginning of the week have now almost been made up.
According to the company, the participants achieved a significant weight reduction of up to 14.5 percent within 36 weeks. At the same time, blood glucose levels also improved measurably: around 89 percent of the test subjects achieved an HbA1c value below seven percent - a clear indication of better blood glucose control.
Amycretin had already impressed in earlier tests with a weight loss of almost 25 percent. What is new about the current study is that for the first time the drug was used specifically in people with type 2 diabetes. The active ingredient was used both as an injection - in six weekly doses with increasing amounts - and in tablet form with three daily doses.
Source: www.derauktionaer.de
